Model | Human sample | cGAS-STING activity | dsDNA levels | Intervention | Changes in dsDNA, cGAS-STING after Intervention | Intervention effect | References |
---|---|---|---|---|---|---|---|
APP/PS1 mice; Aβ induced HMC3 human microglial cells | - | Upregulated cGAS, STING | Increased cytosolic mtDNA level | NAD+ | Decreased cytoplasmic mtDNA, cGAS, STING levels | Reduced neuroinflammation; improved cognition impairment and synaptic plasticity; prevented cellular senescence; promoted the protective microglial phenotype | [167] |
5xFAD mice | Hippocampal region of AD patients | Upregulated cGAS, STING | Increased cytosolic mtDNA level | Cgas − / − ; RU.521; H-151 | Suppressed the activation of the cGAS-STING pathway | Alleviated cognitive impairment, Aβ pathology, neuroinflammation; inhibited neurotoxic A1 astrocytic phenotype in microglia | [145] |
APP/PS1 mice | - | Upregulated cGAS, STING | Increased cytosolic dsDNA level | Tetrahydroxy stilbene glycoside | Decreased cGAS, STING; alleviated the accumulation of cytosolic DNA | Ameliorated neuroinflammation; improved cognition impairment; inhibited the polarization of microglia toward M1-type | [169] |
5 × FAD mice | - | Upregulated cGAS, STING | - | Cgas deletion; H-151 | - | Suppressed the formation of neurotoxic A1 astrocytes; decreased oligomeric Aβ-induced neuronal toxicity | [170] |
5xFAD mice | AD patients | Upregulated cGAS, STING | - | Microglia-specific cGAS knockout | - | Alleviated Aβ-induced cognitive impairment; limited plaque formation; reduced the levels of dystrophic neurites | [117] |
APP/PS1 mice; sporadic AD patients derived-human skin fibroblast cell line | - | Upregulated cGAS, STING | Increased mtDNA level | NR | Elevated the cGAS-STING was normalized; reduced cytoplasmic DNA levels | Increased mitophagy; reduced neuroinflammation and cellular senescence; improved cognition and behavior; promotes anti-inflammatory microglial polarization | [171] |
- | Temporal lobe of AD patients | Impaired cGAS-STING-interferon signaling | Increased dsDNA damage | - | - | - | [172] |
PLD3 deficient SH-SY5Y cells | - | Upregulated cGAS, STING | Increased mtDNA level in lysosomes and cytoplasm | APP knockout; H151 | Lowered STING activation; | Normalized APP-CTF levels and cholesterol biosynthesis | [173] |
- | AD patients, dapsone, and anti-AD drug users in Hansen subjects | - | - | Dapsone (cGAS-STING pathway inhibitor) | - | Prevented AD exacerbation | [174] |
APP/PS1 mice | AD patients | Downregulated cGAS, STING | Increased cytosolic mtDNA level | Melatonin | Promoting the cGAS-STING signaling; Ameliorated cytosolic mtDNA accumulation | Ameliorated APP/PS1-induced changes in cardiac geometry and function, apoptosis, mitochondrial integrity, and mitophagy | [175] |
AD patient derived-iPSCs | - | Upregulated cGAS, STING | Increased cytosolic RNA–DNA hybrids level | c-Jun inhibition | Rescue RNA–DNA hybrid formation and the cGAS-STING activation | Rescued neuronal death and the impaired neurogenesis phenotype in AD progenitors | [166] |
Aβ induced microglia | - | Upregulated cGAS, STING | - | RU.521; C-176; IFITM3 Knockdown | Decreased cGAS, STING | Suppressed the M1-like polarization of microglia; reduced neuroinflammation | [176] |
APP/PS1 mice; Aβ induced HT22, N2a and SK‐N‐BE cell lines | - | Upregulated STING | Increased mtDNA leakage | Knocking out STING | Decreased STING | Inhibited Aβ1–42 and mtDNA induced neuron degeneration and cognitive impairment | [177] |
STZ-treated HT22 murine hippocampal neurons; ICV-STZ rats | - | Upregulated STING | - | Silibinin | Decreased STING | Promoted survival of STZ-treated HT22 cells; ameliorates the cognitive impairment and anxiety/depression-like behavior of ICV-STZ rats; reduces STING-mediated neuroinflammation | [178] |
P301S transgenic mice; tau induced microglia | AD patients | Upregulated cGAS, STING | Increased cytosolic mtDNA level | Cgas loss; TDI-6570 | - | Restored synaptic integrity, plasticity and memory | [103] |
APP/PS1 mice | - | Downregulated STING | - | cGAMP | Upregulated the expression of STING | Ameliorates cognitive deficits; improved pathological changes; decreases Aβ plaque load and neuron apoptosis | [179] |
AppNL−G−F/hTau double-knock-in mice; APOE ε4 human iPSC-derived microglia; Primary microglia treated with Aβ and tau | - | Upregulated cGAS, STING | Increased cytosolic mtDNA level | H-151; SN-011; STING knockout | Decreased STING | Reduced a wide range of AD pathogenic features; reduced gliosis and cerebral inflammation; prevented memory loss | [180] |
APOE4-R47H female tauopathy mice | - | Upregulated cGAS, STING | Increased cytosolic mtDNA level | - | - | - | [181] |